Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia
Haematologica
.
2021 Feb 1;106(2):574-579.
doi: 10.3324/haematol.2019.226795.
Authors
Aniket Bankar
1
,
Thirushi Piyumika Siriwardena
1
,
Biljana Rizoska
2
,
Christina Rydergård
3
,
Helen Kylefjord
3
,
Vilma Rraklli
3
,
Anders Eneroth
3
,
Pedro Pinho
3
,
Stefan Norin
3
,
Johan Bylund
3
,
Sara Moses
3
,
Richard Bethell
3
,
Simon Kavanagh
1
,
Neil Maclean
1
,
Marcela Gronda
1
,
Xiaoming Wang
1
,
Rose Hurren
1
,
Mark D Minden
1
,
Paul Targett-Adams
3
,
Aaron D Schimmer
1
,
Mark Albertella
3
Affiliations
1
Princess Margaret Cancer Center, University Health Network, Ontario, Canada.
2
Medivir AB,Huddinge, Sweden.
3
Medivir AB, Huddinge, Sweden.
PMID:
31857370
PMCID:
PMC7849559
DOI:
10.3324/haematol.2019.226795
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Cytarabine
Humans
Leukemia, Myeloid, Acute* / drug therapy
Nucleosides*
Substances
Nucleosides
Cytarabine
Grants and funding
CIHR/Canada